Project Grant K24HL177172
Award Date 8/1/26
Completion Date 5/31/31
Dollars Obligated $127K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, DC 20010, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $128,466 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a patient-oriented research program led by Dr. Elizabeth Foglia, an Associate Professor of Pediatrics in the Division of Neonatology, focused on improving neonatal respiratory outcomes by optimizing non-invasive ventilation and improving neonatal airway management. The award funds a K24 mentoring...
- The National Heart, Lung, and Blood Institute awarded Children's Research Institute $1,818,088 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how postnatal hypoxemia—reduced blood oxygen levels present in cyanotic congenital heart disease—impacts cardiac maturation and surgical recovery outcomes in pediatric patients. The project will examine the interaction between hypoxemia, myocardial immaturity, and postoperative complications through...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded Boston Children's Hospital $171,600 on September 1, 2026, under CFDA 93.837 (Cardiovascular Diseases Research) to support career development and mentored research in pediatric obstructive sleep apnea diagnostics. The award funds the recipient investigator's training in three areas: predictive modeling and machine learning, advanced physiological signal analysis, and implementation science for translating research into clinical...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $1,741,543 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung injury in pediatric hematopoietic cell transplant recipients. The research examines molecular mechanisms of pulmonary toxicity in pediatric HCT recipients, who experience lung injury in up to 40% of cases with mortality rates of 40% when requiring...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. a K24 Project Grant totaling $266,442 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research and mentorship activities on mechanisms of airway inflammation and remodeling in chronic rhinosinusitis and asthma. The research plan tests three epithelial-centric hypotheses: epithelial metabolic reprogramming in chronic rhinosinusitis with nasal polyps...
- The National Heart, Lung, and Blood Institute awarded Boston Children's Hospital $1,561,052 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate pulmonary ionocyte function and development using human induced pluripotent stem cell-derived airway epithelium. Performance runs through June 30, 2030, in Boston, Massachusetts. The project addresses gaps in understanding how pulmonary ionocytes—rare airway cells marked by FOXI1 and ASCL3 expression and...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded National Jewish Health $249,000 on July 24, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate rare airway cell function in post-viral chronic inflammation. The research examines the role of microfold (M) cells in the post-influenza lung, particularly their contribution to secondary bacterial infection susceptibility and host protection. Using single-nucleus transcriptomic and...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $876,614 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a multisite prospective cohort study advancing acute respiratory infection treatment in pediatric invasive home mechanical ventilation. The research will enroll 400 children in English and Spanish language families using long-term home mechanical...
- The National Heart, Lung, and Blood Institute awarded Cincinnati Children's Hospital Medical Center $331,340 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate dynamic free-breathing 129Xe MRI as a non-invasive functional lung imaging tool for pediatric populations including neonates, infants, toddlers, and young children. The project addresses limitations of current clinical assessment methods for pediatric lung diseases such as...
- The National Heart Lung and Blood Institute awarded the Regents of the University of Michigan $134,439 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support mentoring in translational interstitial lung disease research. The award funds development of protein-based biomarkers for patients with fibrotic interstitial lung disease (ILD) through two primary objectives: deriving and validating a proteomic biomarker to predict ILD in patients presenting with...